


Figure 1A – Figure 1D




Figure 1E – Figure 1G




Figure 2A – Figure 2B




Figure 3A – Figure 3C



ZIKV challenge at 5 weeks
ZIKV prM–E mRNA–LNP
Control
600 µg
200 µg
50 µg
Viral RNA copies per ml
10^6
10^5
10^4
10^3
10^2
10^1
1
3
5
7
Days after infection

Figure 4




Figure 5A – Figure 5C



Kd
50
37
Secreted
Zika Mex 2-81 virus
Untransfected
Polynesian prM-E mRNA
Luciferase mRNA
Mex 2-81 prM-E mRNA
Cell associated
Mex 2-81 virus
Uninfected Vero
293T Luc mRNA
293T prM-E mRNA
Human DC Luc mRNA
Human DC prM-E mRNA
Murine DC Luc mRNA
Murine DC prM-E mRNA

Figure 6



% of CD4+ T cells expressing indicated cytokine(s)
0.06
0.04
0.02
0.00
poly(C) RNA-LNP
ZIKV prM-E mRNA LNP
*
IFNγ
TNFα
IL-2
+ + +
+ + -
+ - +
+ - -
- + +
- + -
- - +
- - -

Figure 7




Figure 8A – Figure 8B



% plaque forming units
100
80
60
40
20
0
5
0.5
0.05
0.005
no mAb
Concentration of Ab3594 (μg ml-1)

Figure 9




Figure 10A – Figure 10B